Dexmedetomidine and Clonidine

Mechanism

🧬 Dexmedetomidine

• Selectivity α₂:α₁: 1620:1 (highly selective).
• Half-life: 2.0 hours.
• Induces a state of conscious and cooperative sedation from which the patient can be easily awakened by direct verbal stimulation.

💊 Clonidine

• Selectivity α₂:α₁: 220:1 (moderate).
• Half-life: 12.0 hours.
• Use mainly orally, transdermally or intrathecal/epidurally as a long-term adjuvant in regional anesthesia.

Mechanism of action

Dexmedetomidine selectively activates pre- and postsynaptic α₂-adrenergic receptors coupled to G_i inhibitory proteins located predominantly in the locus coeruleus of the brain stem, the central modulating nucleus of the waking state.

Presynaptic activation inhibits adenylate cyclase and decreases the conductance of L-type calcium channels, drastically reducing the release of norepinephrine at the central synaptic level. The analgesic mechanism is located at the level of the posterior horns of the spinal cord, where the activation of presynaptic α₂ receptors in primary afferent fibers and postsynaptic receptors in second-order projection neurons inhibits the release of substance P and nociceptive glutamate.

Preservation of the Respiratory Reflex

Unlike conventional hypnotics or opioids, dexmedetomidine does not exert clinically relevant repressive effects on the response of the bulbar respiratory center to carbon dioxide (CO₂), keeping minute volume and arterial oxygenation stable even at full sedative doses. This positions it as the option of choice for performing intubations in awake patients with suspected difficult airways or functional craniotomies with intraoperative speech monitoring.

Pharmacokinetics

Pharmacokinetics

• Metabolism: Extensive hepatic through direct glucuronidation and microsomal hydroxylation mediated by the CYP2D6 system.
• Excretion: Renal 95% as soluble conjugated inactive metabolites.
• Typical Cardiovascular Effects: Rapid administration of an initial bolus can cause transient self-limiting hypertension due to peripheral activation of α_2B receptors in vascular smooth muscle, followed by persistent sinus bradycardia and arterial hypotension mediated centrally by decreased central sympathetic tone.

Indicators and dose

Dosage and Clinical Adjustment

• Sedation in Critical Care: Continuous infusion of 0.2 - 1.4 µg/kg/hour without prior loading bolus to avoid extreme bradycardia or cardiac conduction blocks.
• Adjunct to Anesthetic Induction (Intraoperative): Slow loading bolus of 0.5 - 1.0 µg/kg administered over 10-20 minutes, followed by maintenance infusion of 0.2 - 0.7 µg/kg/hour.
• Hepatic Adjustment: Reduce the maintenance dose by 30% - 50% in severe hepatic dysfunction (Child-Pugh C) due to prolonged clearance of the compound.